CytomX Therapeutics Stock News

- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 -

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promoti

When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny sto

Not long ago, GameStop (NYSE: GME ) stock soared and then tanked on the meme-stock waves. A company that went along for the ride was CytomX Therapeutics (NASDAQ: CTMX ), as CytomX Therapeutics stock t

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May

CytomX Therapeutics (NASDAQ: CTMX ) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company. CytomX Therapeutics latest clinical tra

CytomX Therapeutics Inc reported favourable results for its ongoing trial of CX-904 on Thursday. Shares of the biotech firm are still down about 30% at writing.

- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall -

- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors -

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -

CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength

CytomX (NASDAQ: CTMX ) stock is rocketing higher on Wednesday after the company provided investors with an update for its upcoming earnings report. The oncology-focused biopharmaceutical company told

- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study -